根治性放化疗后FDG-PET显像对临床淋巴结阳性食管鳞癌患者预后分组的研究:有利组与不利组
本研究基于前瞻性数据库纳入108例接受放化疗的临床淋巴结阳性食管鳞癌患者,其中59例接受根治性放化疗。放化疗后PET显示无FDG高摄取转移淋巴结且原发灶至少部分缓解定义为yPET-F组。yPET-F组总生存和无远处转移生存显著优于yPET-U组,多因素分析中yPET-F是总生存和无远处转移生存的独立有利预后因素。
要点
- 放化疗后PET无FDG高摄取转移淋巴结且原发灶至少部分缓解定义为yPET-F有利组。
- 根治性放化疗队列中yPET-F组2年总生存72.5% vs yPET-U组13.7%,差异有统计学意义。
- yPET-F组2年无远处转移生存71.6% vs yPET-U组36.6%,差异有统计学意义。
核心结论
- 放化疗后PET显示无FDG高摄取转移淋巴结且原发灶至少部分缓解(即yPET-F状态)预示接受根治性放化疗的临床淋巴结阳性食管鳞癌患者有极好的总生存和无远处转移生存,可能堪比三联治疗。
研究设计与样本
- 从前瞻性收集的数据库中识别108例接受放化疗(伴或不伴切除)的合格患者,研究队列为59例接受根治性放化疗的患者,45例接受三联治疗的患者作为对比组,4例因放化疗后PET发现间期远处转移被排除。
- 采用Kaplan-Meier法进行生存分析,Cox回归进行多因素分析。
主要发现
- 研究队列中位随访41个月。
- Kaplan-Meier分析显示,yPET-F组总生存显著优于yPET-U组(2年:72.5% vs 13.7%,p < 0.01)。
- yPET-F组无远处转移生存显著优于yPET-U组(2年:71.6% vs 36.6%,p = 0.01)。
- 多因素分析中,yPET-F在根治性放化疗队列中仍是总生存(HR 0.08,p < 0.01)和无远处转移生存(HR 0.14,p = 0.02)的强独立有利预后因素。
- 与三联治疗队列相比,yPET-U患者中三联治疗的总生存优于可手术根治性放化疗(p = 0.03),可手术根治性放化疗的总生存优于不可手术根治性放化疗(p = 0.04);yPET-F患者中三组间总生存(p > 0.99)和无远处转移生存(p = 0.92)均无差异。
关键数值与推荐
- yPET-F定义为放化疗后PET显示无FDG高摄取转移淋巴结且原发灶至少部分缓解,否则为yPET-U。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to examine the prognostic value of post-CRT PET based on the presence or absence of FDG-avid metastatic lymph node(s) and metabolic response of the primary tumor in patients with clinically node-positive ESCC treated with definitive chemoradiotherapy (dCRT). METHODS: We identified 108 eligible patients treated by chemoradiotherapy (CRT) with or without resection from our prospectively collected database. Absence of FDG-avid metastatic lymph node with at least partial response of the primary tumor on PET scan after initial CRT was defined as the Post-CRT PET favorable group (yPET-F), and otherwise as unfavorable group (yPET-U). The Kaplan-Meier method and Cox regression were performed for survival analyses and multivariable analysis, respectively. RESULTS: The study cohort was comprised of 59 patients receiving dCRT. Forty-five patients receiving trimodality therapy (TMT) comprised the comparative group and four patients were excluded from further analyses for developing interval distant metastasis detected on post-CRT PET scan. The median follow-up for the study cohort was 41 months. On K-M analysis of the study cohort, yPET-F was found to have significantly better OS (2-year: 72.5% vs 13.7%, p < 0.01) and DMFS (2-year: 71.6% vs 36.6%, p = 0.01) than yPET-U. In multivariable analysis, yPET-F remained as a strong independent favorable prognosticator on both OS (HR 0.08, p < 0.01) and DMFS (HR 0.14, p = 0.02) for the dCRT cohort. Compared with TMT cohort, for yPET-U patients, TMT had better OS (p = 0.03) than dCRT-Operable and dCRT-Operable had superior OS (p = 0.04) than dCRT-Unresectable. For yPET-F patients, there was no difference in both OS (p > 0.99) and DMFS (p = 0.92) between these three groups. CONCLUSIONS: Absence of FDG-avid metastatic lymph node with at least partial response of the primary tumor on PET scan after CRT (i.e., yPET-F status) prognosticate for excellent OS and DMFS in cN+ ESCC patients treated with dCRT, and might be comparable to TMT.
引用
- Yap WK, Chang YC, Hsieh CH, et al. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 29188300. doi:10.1007/s00259-017-3901-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。